Colorectal Cancer Therapeutics Market Share

North America Market Forecast

The North America region colorectal cancer therapeutics market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037. The escalating incidences of colorectal cancer coupled with supportive government initiatives, rising healthcare expenditure, rising number of colon cancer, and increasing awareness among people regarding the screening of colorectal cancer. For instance, the third most prevalent cancer in the United States is colorectal cancer. Around 105,280 new cases of colon cancer and 45,760 new cases of rectal cancer are estimated to be diagnosed in 2022.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of colorectal cancer therapeutics is evaluated at USD 24.11 billion.

The colorectal cancer therapeutics market size was over USD 22.36 billion in 2024 and is projected to reach USD 75.39 billion by 2037, witnessing around 9.8% CAGR during the forecast period i.e., between 2025-2037. Worldwide increasing prevalence of cancer, emerging novel therapies for cancer treatment, significant research on novel drugs, and global surge in geriatric population will boost the market growth.

North America industry is predicted to dominate majority revenue share of 31% by 2037, driven by escalating incidences of colorectal cancer coupled with supportive government initiatives along with rising healthcare expenditure, rising number of colon cancer, and increasing awareness among people regarding the screening of colorectal cancer in the region.

The major players in the market include Novartis AG, Pfizer Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Bayer AG, Amgen Inc., Genentech, Inc., Teva Pharmaceuticals Industries Ltd., Ipsen Biopharmaceuticals, Inc.

Colorectal Cancer Therapeutics Market Share